(vianews) - the market ended the session with gensight biologics (sight.pa) jumping 9.14% to €0.37 on thursday, after five successive sessions in a row of losses. cac 40 jumped 0.71% to €7,665.63, following the last session's downward trend on what was a somewhat up trend exchanging session today.
gensight biologics's last close was €0.34, 91.26% below its 52-week high of €3.88.
about gensight biologics
gensight biologics s.a., a clinical-stage biotechnology company, discovers, develops, and commercializes therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system. the company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms. its lead product candidates include lumevoq (gs010), a recombinant aav2-based gene therapy, which is in phase iii clinical trials for the treatment of leber hereditary optic neuropathy caused by a mutated nd4 gene; and gs030, which is in phase i/ii clinical trial for the treatment of retinitis pigmentosa, as well as in preclinical stage to treat dry age-related macular degeneration. the company is also developing products that are in preclinical stage targeting ophthalmic and neurodegenerative diseases. the company was incorporated in 2012 and is headquartered in paris, france.
earnings per share
as for profitability, gensight biologics has a trailing twelve months eps of €-0.63.
volume
today's last reported volume for gensight biologics is 187451 which is 54.23% above its average volume of 121539.
yearly top and bottom value
gensight biologics's stock is valued at €0.37 at 21:37 est, below its 52-week low of €0.38.
stock price classification
according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, gensight biologics's stock is considered to be overbought (>=80).
more news about gensight biologics (sight.pa).